Biotech Targets ‘Blockbuster’ Markets; Less-Addictive Opioid Painkiller Set for FDA Filing

Source: John McCamant for Streetwise Reports   11/15/2017 Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that, in addition . . . → Read More: Biotech Targets ‘Blockbuster’ Markets; Less-Addictive Opioid Painkiller Set for FDA Filing Similar Articles: Biotech with Solid Pipeline and ‘Solid Partnership Outlook’ Maxim Raises Target Price of Biotech Company 2017 Small-Cap Biotech Watchlist Update: Up 21% at the End of Q2/17